The ICAR-Central Marine Fisheries Research Institute (CMFRI) has successfully commercialized two seaweed-based nutraceutical products designed to enhance anti-viral immunity and combat high cholesterol or dyslipidemia. The institute signed a license agreement with Pioneer Pharmaceuticals Ltd, a wellness and pharmaceutical company based in Kochi, for the commercial production and marketing of these patent-protected products.
The products, known as Cadalmin™ Immunalgin extract (Cadalmin™ IMe) and Cadalmin™ Antihypercholesterolemic extract (Cadalmin™ ACe), are formulated from bioactive ingredients extracted with eco-friendly ‘green’ technology. Dr. A Gopalakrishnan, Director of CMFRI, emphasized that these nutraceuticals are 100% natural blends, harnessing the nutritional benefits of seaweeds commonly found in Indian coastal waters.
Cadalmin™ IMe, the anti-viral immunity booster, is touted as a potential remedy against post-COVID complications, exhibiting antiviral properties against the delta variant of the SAARS CoV-2 virus. Dr. Kajal Chakraborty, Head of the Marine Biotechnology, Fish Nutrition and Health Division at CMFRI, highlighted its ability to elevate immune responses by regulating the secretion of pro-inflammatory cytokines and chemokines. The product is positioned as a naturally derived alternative source for health benefits against inflammation and autoimmune disorders.
On the other hand, Cadalmin™ ACe has been developed as a natural remedy for dyslipidemia and hypercholesterolemic disorders. Dr. Chakraborty explained that the product, derived from seaweed concentrate, demonstrates anti-dyslipidemic activities following a series of purification steps.
Dr. Gopalakrishnan outlined CMFRI’s future plans, indicating ongoing efforts to develop more health products from seaweeds in alignment with the National Policy. Seaweeds, often termed as the ‘wonder herbs of the ocean,’ hold immense potential for pharmaceuticals and food for human well-being. CMFRI has successfully introduced nutraceuticals targeting various lifestyle diseases, including type-2 diabetes, arthritis, hypertension, hypothyroidism, osteoporosis, and fatty liver.
Pioneer Pharmaceuticals is expected to make these seaweed-based nutraceuticals available in the market within the next six months, marking a significant stride in leveraging the natural wealth of Indian coastal waters for health and well-being.
